SRSF2 and acute myeloid leukemia: Venetoclax (VEN) has proven to be as effective as monotherapy, especially in AML harboring IDH1/2 and SRSF2/ZRSF2 mutations (Daver et al., 2020; George et al., 2021; Thijssen et al., 2021).